Selective gene delivery for cancer therapy using cationic liposomes: in vivo proof of applicability
Crispin R Dass1, Peter F M Choong
1Department of Orthopaedics, University of Melbourne, St. Vincent's Hospital Melbourne, P.O. Box 2900, Fitzroy 3065, Australia. crispin.dass@svhm.org.au
Abstract:
Targeted gene therapy is essential if cancer treatment is to become a reality with this form of therapy. In the past few years, cationic liposomes, discovered 2 decades ago, and at present, the most commonly used class of transfection reagents, have been tested in various clinical trials for diseases not restricted to cancer. They have been shown to be selective for tumour vascular endothelial cells raising hopes for antiangiogenic and antivascular therapies. They are also capable of being selectively delivered to the lungs and liver when administered intravenously. These vesicles are also being targeted to the tumour in various parts of the body by using advanced liposomal systems such as antibody-antigen and ligand-receptor combinations. This review looks at the state of play in this rapidly growing field.
Insights
Cationic liposomes are key to targeted gene therapy for cancer. These advanced liposomal systems show promise for antiangiogenic and antivascular therapies, with selective delivery to tumors and organs.
Area of Science:
- Biomedical Engineering
- Oncology
- Nanotechnology
Background:
- Cationic liposomes, a widely used transfection reagent class, have been explored in clinical trials for various diseases, including cancer.
- These liposomes demonstrate selectivity for tumor vascular endothelial cells, suggesting potential for antiangiogenic and antivascular strategies.
- Intravenous administration allows for selective delivery to organs like the lungs and liver.
Purpose of the Study:
- To review the current state of targeted gene therapy using advanced liposomal systems.
- To highlight the potential of cationic liposomes in cancer treatment and other diseases.
- To discuss novel targeting strategies for liposomes in various body parts.
Main Methods:
- Review of existing literature on cationic liposomes and targeted gene therapy.
- Analysis of clinical trial data for liposome-based therapies.
- Examination of advanced liposomal systems, including antibody-antigen and ligand-receptor targeting.
Main Results:
- Cationic liposomes exhibit selective targeting of tumor vascular endothelial cells.
- Demonstrated selective delivery to lungs and liver upon intravenous administration.
- Advanced liposomal systems enable tumor targeting in various body locations.
Conclusions:
- Targeted gene therapy using cationic liposomes is crucial for advancing cancer treatment.
- Liposome-based strategies offer significant potential for antiangiogenic and antivascular therapies.
- Ongoing advancements in liposomal systems are expanding their therapeutic applications.
